Clinicopathological features of ALect2 amyloidosis
| Case . | Age (y) . | Sex . | Ethnicity . | Presentation . | Histological pattern . | Other pathology . | MS results . | LECT2 IHC . |
|---|---|---|---|---|---|---|---|---|
| 1 | 65 | M | Caucasian | N/A | Portal/globular | Steatohepatitis | ALect2 | + |
| 2 | 41 | M | Caucasian | N/A | Portal/globular | Chronic hepatitis C | ALect2 | + |
| 3 | 60 | M | Caucasian | Incidental* | Portal/globular | Chronic hepatitis C | ALect2 | + |
| 4 | 70 | F | Hispanic | Cirrhosis, ascites, hepatitis | Portal/globular | Chronic hepatitis unknown type | ALect2 | + |
| 5 | 52 | F | Hispanic | Elevated LFTs | Portal/globular | Steatohepatitis | ALect2 | + |
| 6 | 65 | M | Hispanic | Elevated LFTs | Portal/globular | - | ALect2 | + |
| 7 | 76 | M | Hispanic | N/A | Portal/globular | - | ALect2 | + |
| 8 | 65 | F | Hispanic | Incidental* | Portal/globular | Steatosis | ALect2 | + |
| 9 | 62 | F | Hispanic | Incidental* | Portal/globular | Lymphocytic infiltrate | ALect2 | + |
| 10 | 58 | F | Caucasian | Incidental* | Portal/nodular | - | ALect2 | + |
| 11 | 62 | F | Hispanic | Elevated LFTs | Portal/globular | - | ALect2 | + |
| 12 | 36 | M | Hispanic | Elevated LFTs | Portal/globular | Lymphocytic infiltrate | ALect2 | + |
| 13 | 72 | F | Hispanic | Incidental* | Portal/nodular | - | ALect2 | + |
| 14 | 60 | F | Hispanic | N/A | Portal/globular | Lymphocytes infiltrate | ALect2 | + |
| 15 | 61 | F | Hispanic | Elevated LFTs | Portal/globular | Steatosis | ALect2 | + |
| 16 | 52 | F | Hispanic | Incidental* | Portal/globular | Cirrhosis, steatohepatitis | ALect2 | + |
| 17 | 79 | F | Hispanic | Elevated LFTs | Portal/globular | - | ALect2 | + |
| 18 | 63 | M | Hispanic | Elevated LFTs | Portal/globular | Cirrhosis | ALect2 | + |
| 19 | 54 | F | Hispanic | Elevated LFTs | Portal/globular | Steatosis, lymphocytic infiltrate | ALect2 | + |
| 20 | 74 | F | Hispanic | Incidental* | Portal/globular | Cirrhosis | ALect2 | + |
| 21 | 59 | M | Hispanic | N/A | Portal/globular | - | ALect2 | + |
| 22 | 61 | M | Hispanic | N/A | Portal/globular | - | ALect2 | + |
| 23 | 69 | M | Hispanic | N/A | Portal/globular | Chronic hepatitis C, portal fibrosis | ALect2 | + |
| 24 | 59 | M | Hispanic | N/A | Portal/globular | Lymphocytic infiltrate | ALect2 | + |
| 25 | 52 | F | Hispanic | N/A | Portal/globular | - | ALect2 | + |
| 26 | 53 | F | Hispanic | N/A | Portal/globular | - | ALect2 | + |
| 27 | 79 | F | Hispanic | N/A | Portal/globular | - | ALect2 | + |
| 28 | 66 | F | Hispanic | N/A | Portal/globular | Lymphocytic infiltrate | ALect2 | + |
| 29 | 33 | F | Hispanic | N/A | Portal/globular | Steatosis | ALect2 | + |
| 30 | 52 | M | Hispanic | Portal hypertension | Portal/globular | Steatohepatitis | ALect2 | + |
| 31 | 59 | F | Hispanic | Elevated LFTs | Portal/globular | Lymphocytic infiltrate | ALect2 | + |
| 32 | 52 | F | Hispanic | Elevated LFTs | Portal/globular | Steatohepatitis | ALect2 | + |
| Case . | Age (y) . | Sex . | Ethnicity . | Presentation . | Histological pattern . | Other pathology . | MS results . | LECT2 IHC . |
|---|---|---|---|---|---|---|---|---|
| 1 | 65 | M | Caucasian | N/A | Portal/globular | Steatohepatitis | ALect2 | + |
| 2 | 41 | M | Caucasian | N/A | Portal/globular | Chronic hepatitis C | ALect2 | + |
| 3 | 60 | M | Caucasian | Incidental* | Portal/globular | Chronic hepatitis C | ALect2 | + |
| 4 | 70 | F | Hispanic | Cirrhosis, ascites, hepatitis | Portal/globular | Chronic hepatitis unknown type | ALect2 | + |
| 5 | 52 | F | Hispanic | Elevated LFTs | Portal/globular | Steatohepatitis | ALect2 | + |
| 6 | 65 | M | Hispanic | Elevated LFTs | Portal/globular | - | ALect2 | + |
| 7 | 76 | M | Hispanic | N/A | Portal/globular | - | ALect2 | + |
| 8 | 65 | F | Hispanic | Incidental* | Portal/globular | Steatosis | ALect2 | + |
| 9 | 62 | F | Hispanic | Incidental* | Portal/globular | Lymphocytic infiltrate | ALect2 | + |
| 10 | 58 | F | Caucasian | Incidental* | Portal/nodular | - | ALect2 | + |
| 11 | 62 | F | Hispanic | Elevated LFTs | Portal/globular | - | ALect2 | + |
| 12 | 36 | M | Hispanic | Elevated LFTs | Portal/globular | Lymphocytic infiltrate | ALect2 | + |
| 13 | 72 | F | Hispanic | Incidental* | Portal/nodular | - | ALect2 | + |
| 14 | 60 | F | Hispanic | N/A | Portal/globular | Lymphocytes infiltrate | ALect2 | + |
| 15 | 61 | F | Hispanic | Elevated LFTs | Portal/globular | Steatosis | ALect2 | + |
| 16 | 52 | F | Hispanic | Incidental* | Portal/globular | Cirrhosis, steatohepatitis | ALect2 | + |
| 17 | 79 | F | Hispanic | Elevated LFTs | Portal/globular | - | ALect2 | + |
| 18 | 63 | M | Hispanic | Elevated LFTs | Portal/globular | Cirrhosis | ALect2 | + |
| 19 | 54 | F | Hispanic | Elevated LFTs | Portal/globular | Steatosis, lymphocytic infiltrate | ALect2 | + |
| 20 | 74 | F | Hispanic | Incidental* | Portal/globular | Cirrhosis | ALect2 | + |
| 21 | 59 | M | Hispanic | N/A | Portal/globular | - | ALect2 | + |
| 22 | 61 | M | Hispanic | N/A | Portal/globular | - | ALect2 | + |
| 23 | 69 | M | Hispanic | N/A | Portal/globular | Chronic hepatitis C, portal fibrosis | ALect2 | + |
| 24 | 59 | M | Hispanic | N/A | Portal/globular | Lymphocytic infiltrate | ALect2 | + |
| 25 | 52 | F | Hispanic | N/A | Portal/globular | - | ALect2 | + |
| 26 | 53 | F | Hispanic | N/A | Portal/globular | - | ALect2 | + |
| 27 | 79 | F | Hispanic | N/A | Portal/globular | - | ALect2 | + |
| 28 | 66 | F | Hispanic | N/A | Portal/globular | Lymphocytic infiltrate | ALect2 | + |
| 29 | 33 | F | Hispanic | N/A | Portal/globular | Steatosis | ALect2 | + |
| 30 | 52 | M | Hispanic | Portal hypertension | Portal/globular | Steatohepatitis | ALect2 | + |
| 31 | 59 | F | Hispanic | Elevated LFTs | Portal/globular | Lymphocytic infiltrate | ALect2 | + |
| 32 | 52 | F | Hispanic | Elevated LFTs | Portal/globular | Steatohepatitis | ALect2 | + |
LFT: Liver function tests; N/A: data not available.
Liver biopsy performed during surgery for other diseases (cholecystectomy in 3 cases, allograft biopsy during laparotomy, and small bowel resection for partial obstruction caused by adhesions in 1 case, and biopsy of benign liver cysts in 1 case), or liver transplantation for hepatocellular carcinoma/end-stage liver disease (1 allograft liver biopsy and 1 explanted liver biopsy).